{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:53:00Z","timestamp":1774288380835,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82102941"],"award-info":[{"award-number":["82102941"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82103483"],"award-info":[{"award-number":["82103483"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the National Key R&D Program of China","award":["2022YFC2503700"],"award-info":[{"award-number":["2022YFC2503700"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14367-7","type":"journal-article","created":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T08:23:17Z","timestamp":1748161397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of combining tislelizumab with capecitabine compared to capecitabine alone in the adjuvant treatment of biliary tract cancers: rationale and protocol design for a randomized clinical trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Xubiao","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yabo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinxue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongkun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaxin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuqun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,25]]},"reference":[{"issue":"2","key":"14367_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, Kelley RK, Klumpen HJ, Malka D, Primrose JN, Rimassa L, Stenzinger A, Valle JW, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127\u201340.","journal-title":"Ann Oncol"},{"issue":"12","key":"14367_CR2","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1200\/JCO.18.02178","volume":"37","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, El-Khoueiry A, Feng M, Katz MHG, Primrose J, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37(12):1015\u201327.","journal-title":"J Clin Oncol"},{"key":"14367_CR3","doi-asserted-by":"publisher","first-page":"175883592311637","DOI":"10.1177\/17588359231163785","volume":"15","author":"J Kefas","year":"2023","unstructured":"Kefas J, Bridgewater J, Vogel A, Stein A, Primrose J. Adjuvant therapy of biliary tract cancers. Ther Adv Med Oncol. 2023;15:17588359231163785.","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"14367_CR4","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, Anthony A, Corrie P, Falk S, Finch-Jones M, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663\u201373.","journal-title":"Lancet Oncol"},{"issue":"10372","key":"14367_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","volume":"401","author":"K Nakachi","year":"2023","unstructured":"Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T, Todaka A, Yanagimoto H, Morinaga S, Kobayashi S, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2023;401(10372):195\u2013203.","journal-title":"Lancet"},{"issue":"8","key":"14367_CR6","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","volume":"70","author":"J Vincent","year":"2010","unstructured":"Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, R\u00e9b\u00e9 C, Ghiringhelli F. 5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70(8):3052\u201361.","journal-title":"Cancer Res"},{"key":"14367_CR7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3389\/fonc.2020.00492","volume":"10","author":"M Zhang","year":"2020","unstructured":"Zhang M, Fan Y, Che X, Hou K, Zhang C, Li C, Wen T, Wang S, Cheng Y, Liu Y, et al. 5-FU-induced upregulation of exosomal PD-L1 causes immunosuppression in advanced gastric cancer patients. Front Oncol. 2020;10:492.","journal-title":"Front Oncol"},{"key":"14367_CR8","doi-asserted-by":"crossref","unstructured":"Li X, Li Y, Dong L, Chang Y, Zhang X, Wang C, Chen M, Bo X, Chen H, Han W et al. Decitabine priming increases anti-PD-1 antitumor efficacy by promoting CD8\u2009+\u2009progenitor exhausted T cell expansion in tumor models. J Clin Invest. 2023;133(7).","DOI":"10.1172\/JCI165673"},{"issue":"8","key":"14367_CR9","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, Ruth He A, Qin S, Chen L-T, Okusaka T, Vogel A, Kim JW, Suksombooncharoen T, Ah Lee M, Kitano M, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015.","journal-title":"NEJM Evid"},{"issue":"1","key":"14367_CR10","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/s41467-023-37030-w","volume":"14","author":"TM Zeng","year":"2023","unstructured":"Zeng TM, Yang G, Lou C, Wei W, Tao CJ, Chen XY, Han Q, Cheng Z, Shang PP, Dong YL, et al. Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer. Nat Commun. 2023;14(1):1340.","journal-title":"Nat Commun"},{"issue":"10391","key":"14367_CR11","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klumpen HJ, Chan SL, Ozaka M, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853\u201365.","journal-title":"Lancet"},{"key":"14367_CR12","unstructured":"SERVICES USDOHAH. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. 2017."},{"issue":"18","key":"14367_CR13","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1200\/JCO.21.02568","volume":"40","author":"J Bridgewater","year":"2022","unstructured":"Bridgewater J, Fletcher P, Palmer DH, Malik HZ, Prasad R, Mirza D, Anthony A, Corrie P, Falk S, Finch-Jones M, et al. Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study. J Clin Oncol. 2022;40(18):2048\u201357.","journal-title":"J Clin Oncol"},{"key":"14367_CR14","doi-asserted-by":"crossref","unstructured":"Bogatsa E, Lazaridis G, Stivanaki C, Timotheadou E. Neoadjuvant and adjuvant immunotherapy in resectable NSCLC. Cancers (Basel). 2024;16(9).","DOI":"10.3390\/cancers16091619"},{"issue":"3","key":"14367_CR15","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41591-023-02786-7","volume":"30","author":"K Wang","year":"2024","unstructured":"Wang K, Xiang Y-J, Yu H-M, Cheng Y-Q, Liu Z-H, Qin Y-Y, Shi J, Guo W-X, Lu C-D, Zheng Y-X, et al. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nat Med. 2024;30(3):708\u201315.","journal-title":"Nat Med"},{"issue":"15","key":"14367_CR16","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMe2402364","volume":"390","author":"MH Voss","year":"2024","unstructured":"Voss MH, Motzer RJ. Adjuvant immunotherapy for kidney cancer - a new strategy with new challenges. N Engl J Med. 2024;390(15):1432\u20133.","journal-title":"N Engl J Med"},{"issue":"19","key":"14367_CR17","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789\u2013801.","journal-title":"N Engl J Med"},{"issue":"6","key":"14367_CR18","doi-asserted-by":"publisher","first-page":"101063","DOI":"10.1016\/j.tranon.2021.101063","volume":"14","author":"JT J\u00f8rgensen","year":"2021","unstructured":"J\u00f8rgensen JT. The current landscape of the FDA approved companion diagnostics. Transl Oncol. 2021;14(6):101063.","journal-title":"Transl Oncol"},{"key":"14367_CR19","doi-asserted-by":"publisher","first-page":"1321813","DOI":"10.3389\/fimmu.2024.1321813","volume":"15","author":"SB Yoon","year":"2024","unstructured":"Yoon SB, Woo SM, Chun JW, Kim DU, Kim J, Park JK, So H, Chung MJ, Cho IR, Heo J. The predictive value of PD-L1 expression in response to anti-PD-1\/PD-L1 therapy for biliary tract cancer: a systematic review and meta-analysis. Front Immunol. 2024;15:1321813.","journal-title":"Front Immunol"},{"key":"14367_CR20","doi-asserted-by":"publisher","first-page":"100910","DOI":"10.1016\/j.neo.2023.100910","volume":"42","author":"C Kumar-Sinha","year":"2023","unstructured":"Kumar-Sinha C, Vats P, Tran N, Robinson DR, Gunchick V, Wu Y-M, Cao X, Ning Y, Wang R, Rabban E, et al. Genomics driven precision oncology in advanced biliary tract cancer improves survival. Neoplasia (New York NY). 2023;42:100910.","journal-title":"Neoplasia (New York NY)"},{"issue":"3","key":"14367_CR21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.ajpath.2024.11.005","volume":"195","author":"H Ellis","year":"2025","unstructured":"Ellis H, Braconi C, Valle JW, Bardeesy N. Cholangiocarcinoma targeted therapies: mechanisms of action and resistance. Am J Pathol. 2025;195(3):437\u201352.","journal-title":"Am J Pathol"},{"key":"14367_CR22","doi-asserted-by":"publisher","first-page":"e2100510","DOI":"10.1200\/PO.21.00510","volume":"6","author":"K Mody","year":"2022","unstructured":"Mody K, Jain P, El-Refai SM, Azad NS, Zabransky DJ, Baretti M, Shroff RT, Kelley RK, El-Khouiery AB, Hockenberry AJ, et al. Clinical, genomic, and transcriptomic data profiling of biliary tract cancer reveals subtype-specific immune signatures. JCO Precis Oncol. 2022;6:e2100510.","journal-title":"JCO Precis Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14367-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14367-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14367-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T08:23:19Z","timestamp":1748161399000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14367-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,25]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14367"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14367-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,25]]},"assertion":[{"value":"24 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"938"}}